As of December 15, 2025, Curaleaf Holdings Inc (CURA.CN) reports a Gross Margin of 43.33%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Curaleaf Holdings Inc's Gross Margin
Over recent years, Curaleaf Holdings Inc's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2022-12-31 | 43.33% |
| 2021-12-31 | 47.65% |
| 2020-12-31 | 26.48% |
| 2019-12-31 | 19.85% |
| 2018-12-31 | 38.69% |
This slight upward trend highlights how Curaleaf Holdings Inc manages its operational efficiency and pricing power over time.
Comparing Curaleaf Holdings Inc's Gross Margin to Peers
To better understand Curaleaf Holdings Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Curaleaf Holdings Inc (CURA.CN) | 43.33% |
| NGM Biopharmaceuticals Inc (NGM) | 7775.20% |
| Theravance Biopharma Inc (TBPH) | 100.00% |
| Corcept Therapeutics Inc (CORT) | 98.39% |
| Zogenix Inc (ZGNX) | 94.08% |
| Innoviva Inc (INVA) | 89.80% |
Compared to its competitors, Curaleaf Holdings Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.